GlaxoSmithKline (GSK) PT Set at GBX 1,300 by Credit Suisse Group

GlaxoSmithKline (LON:GSK) has been given a GBX 1,300 ($18.23) price target by Credit Suisse Group in a research report issued to clients and investors on Thursday. The firm presently has a “neutral” rating on the stock. Credit Suisse Group’s price target would suggest a potential upside of 0.70% from the company’s previous close.

A number of other equities research analysts also recently commented on the stock. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline in a research report on Thursday. Deutsche Bank restated a “hold” rating and issued a GBX 1,440 ($20.19) price objective on shares of GlaxoSmithKline in a research report on Thursday. Sanford C. Bernstein set a GBX 1,580 ($22.15) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research report on Wednesday. Liberum Capital restated a “buy” rating and issued a GBX 1,630 ($22.85) price objective on shares of GlaxoSmithKline in a research report on Wednesday. Finally, Kepler Capital Markets restated a “reduce” rating and issued a GBX 1,340 ($18.79) price objective on shares of GlaxoSmithKline in a research report on Monday, February 5th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company. GlaxoSmithKline currently has a consensus rating of “Hold” and an average price target of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (GSK) opened at GBX 1,291 ($18.10) on Thursday. The company has a market cap of $64,010.00 and a PE ratio of 4,164.52. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($17.32) and a 12-month high of GBX 1,724.50 ($24.18).

In other GlaxoSmithKline news, insider Patrick Vallance sold 20,000 shares of GlaxoSmithKline stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total value of £262,000 ($367,358.38). Also, insider Sir Roy Anderson bought 562 shares of the stock in a transaction on Wednesday, February 7th. The stock was purchased at an average cost of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Insiders acquired a total of 581 shares of company stock valued at $743,284 over the last ninety days.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline (GSK) PT Set at GBX 1,300 by Credit Suisse Group” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://sportsperspectives.com/2018/02/10/glaxosmithkline-gsk-pt-set-at-gbx-1300-by-credit-suisse-group.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply